Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate

Lucid 现在正按照 EsoGuard 既定的临床实验室费用表费率提交医疗保险索赔并接收付款。

Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration

C轮优先股私募配售面向现有长期股东，强化了Lucid的资产负债表，延长了其现金跑道，并支持近期的商业化加速。

NEW YORK

纽约

,

，

Oct. 22, 2026

2026年10月22日

/PRNewswire/ --

/美通社/ --

Lucid Diagnostics Inc.

Lucid Diagnostics Inc.

(Nasdaq:

（纳斯达克：

LUCD

LUCD

) ('Lucid' or the 'Company'), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:

）（“Lucid”或“公司”），一家处于商业化阶段的癌症预防医学诊断公司，系 PAVmed Inc.（纳斯达克：

PAVM

肺动静脉畸形

), today announced that it has begun receiving payments from Medicare for its

），今日宣布已开始收到来自联邦医疗保险（Medicare）的付款，用于其

EsoGuard

EsoGuard

®

®

Esophageal DNA Test

食管DNA检测

. The Company also closed a $15.0 million private placement on October 21, 2026, for shares of its newly designated Series C Convertible Preferred Stock (the 'Series C Preferred Stock') to existing long-term shareholders.

此外，公司于2026年10月21日向现有长期股东完成了金额为1,500万美元的私募配售，发行其新指定的C系列可转换优先股（“C系列优先股”）股份。

'Medicare is now paying for EsoGuard,' said

“医疗保险现在为EsoGuard付费，”说

Lishan Aklog, M.D.

Lishan Aklog，医学博士

, Lucid's Chairman and Chief Executive Officer. 'For the first time, Medicare beneficiaries nationwide have fully reimbursed access to the groundbreaking EsoGuard test. This breakthrough marks a seminal moment in our mission to end the scourge of esophageal cancer through precancer testing of at-risk patients.

Lucid 公司董事长兼首席执行官表示：“全国各地的医疗保险受益人首次能够完全报销地接受开创性的 EsoGuard 检测。这一突破标志着我们在通过对高危患者进行癌前检测以终结食管癌祸患的使命中，迎来了一个具有里程碑意义的时刻。”

It opens up significant near-term commercial opportunities that extend beyond primary care, gastroenterology, and geriatric practices. Medicare reimbursement removes a key headwind in our continued engagement with large health systems and will also help accelerate our efforts to secure coverage by commercial payors.

这开辟了重大的近期商业机会，范围超越初级保健、胃肠病学和老年病实践。医疗保险报销消除了我们在与大型医疗系统持续合作中的一个关键阻力，也将有助于加速我们获得商业支付方覆盖的努力。

Our team is laser-focused on translating this pivotal milestone into near-term commercial results, and this financing provides the resources we need to do so.'.

我们的团队正全力以赴，将这一关键里程碑转化为近期的商业成果，而此次融资为我们提供了实现这一目标所需的资源。

On September 22, Lucid

9月22日，Lucid

announced

已宣布

that it would begin submitting Medicare claims for EsoGuard tests performed at one of its two CLIA-certified laboratories. Shortly thereafter, the Company began receiving payments on those claims at the established EsoGuard (PLA code 0114U) Clinical Laboratory Fee Schedule rate of $1,938.01 per test..

其将开始为其两家CLIA认证实验室之一所进行的EsoGuard检测提交医疗保险索赔。不久之后，公司开始按照既定的EsoGuard（PLA代码0114U）临床实验室费用表规定的每次检测1,938.01美元的费率收到这些索赔的付款。

The Series C Preferred Stock was sold at a purchase price of $1,000 per share and is convertible into common stock at a conversion price of $0.3519 per share. Investors in the private placement included holders of a majority of the Company's 12.0% senior secured convertible notes due 2029 (the 'Notes').

C系列优先股以每股1,000美元的购买价格出售，并可按每股0.3519美元的转换价格转换为普通股。参与此次私募配售的投资者包括持有公司大部分2029年到期的12.0%高级有担保可转换票据（“票据”）的持有人。

The Series C Preferred Stock includes customary terms, including certain mandatory conversion events, a dividend and liquidation preference, and an agreement by the Company to file a resale registration statement covering the underlying shares of common stock within 120 days following closing. Participating holders of the Notes also acknowledged that the Company's receipt of payments on submitted Medicare claims as described above has addressed the concerns underlying the Notes' Medicare-related event of default provision.

C轮优先股包含惯常条款，包括某些强制转换事件、股息及清算优先权，以及公司承诺在交割后120天内提交一份涵盖标的普通股的转售注册声明。参与票据的持有人亦确认，公司收到上述已提交的医疗保险索赔款项，已解决票据中与医疗保险相关的违约条款所依据的关切事项。

Lucid intends to use the net proceeds to accelerate its near-term commercial operations and for working capital and general corporate purposes..

Lucid 计划将净收益用于加速其近期商业运营，并用于营运资金及一般企业用途。

Additional details of the Series C Preferred private placement can be found in the Company's Current Report on Form 8-K filed concurrently with the Securities and Exchange Commission.

C轮优先股私募发行的更多详情，请参见公司同时向美国证券交易委员会提交的8-K表格当前报告。

About Lucid Diagnostics

关于 Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:

Lucid Diagnostics Inc. 是一家处于商业化阶段的癌症预防医疗诊断公司，也是 PAVmed Inc.（纳斯达克：

PAVM

肺动静脉畸形

). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's

）。Lucid 专注于数百万患有胃食管反流病（GERD，也称为慢性烧心）的患者，这些患者有发展为食管癌前病变和食管癌的风险。Lucid 的

EsoGuard

EsoGuard

®

®

Esophageal DNA Test

食管DNA检测

, performed on samples collected in a brief, noninvasive office procedure with its

，在通过简短、无创的门诊程序采集的样本上进行，其

EsoCheck

EsoCheck

®

®

Esophageal Cell Collection Device

食管细胞采集装置

, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

，代表了首款也是唯一一款已上市的工具，其设计目标是通过在高风险患者中广泛早期检测食管癌前病变，从而预防癌症及癌症死亡。

For more information, please visit

如需更多信息，请访问

www.luciddx.com

www.luciddx.com

and for more information about its parent company PAVmed, please visit

如需了解更多关于其母公司 PAVmed 的信息，请访问

www.pavmed.com

www.pavmed.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

本新闻稿包含涉及风险和不确定性的前瞻性陈述。前瞻性陈述是指任何非历史事实的陈述。此类前瞻性陈述基于Lucid Diagnostics管理层当前的信念和预期，受风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性陈述存在差异。

Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments.

可能导致此类差异的风险和不确定性包括但不限于：Lucid Diagnostics 普通股价格的波动；总体经济和市场状况；研究与开发中固有的不确定性，包括将 Lucid Diagnostics 的产品推进至监管申报所需的成本和时间；监管机构是否会对 Lucid Diagnostics 临床和非临床研究的设计及结果感到满意；Lucid Diagnostics 的产品是否会获得监管机构批准以及何时获得批准；一旦获得批准并商业化，市场对 Lucid Diagnostics 产品的接受程度；Lucid Diagnostics 在需要时筹集额外资金的能力；以及其他竞争性发展。

These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, 'Risk Factors,' in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics .

这些因素难以或无法准确预测，且其中许多因素超出 Lucid Diagnostics 的控制范围。此外，新的风险和不确定性可能不时出现，且难以预测。有关可能影响 Lucid Diagnostics 未来运营的这些及其他重要风险和不确定性的进一步列表及描述，请参阅 Lucid Diagnostics 向美国证券交易委员会提交的最新 Form 10-K 年度报告中的第一部分第 1A 项“风险因素”，以及 Lucid Diagnostics 提交的任何 Form 10-Q 季度报告的第二部分第 1A 项“风险因素”中对此作出的更新。

SOURCE Lucid Diagnostics

来源：Lucid Diagnostics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示